1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2010-2015

Summary
Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies

Description

The Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all option and evaluation deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.

Chapter 4 provides a review of the leading option and evaluation deals since 2010. Deals are listed by headline value, signed by big pharma and big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2010where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2010.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Benefits

Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2010-2015 provides the reader with the following key benefits:

In-depth understanding of option and evaluation partnering deal trends since 2010
Insight into the terms included in an option and evaluation agreement, together with real world clause examples
Identify leading option and evaluation deals by value since 2010
Identify the most active option and evaluation dealmakers since 2010
Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
Full listing of option and evaluation deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
Comprehensive access to over 1,000 option and evaluation deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual option and evaluation contracts entered into by the leading fifty big pharma and big biotech companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

option. evaluation, partnering, licensing, alliances, pharma deals, biotech deals, pharmaceutical licensing, biotech licensing, big pharma, top pharma, pharma partnering, Abbott, Actavis, Watson Pharmaceuticals, Actelion, Allergan, Amgen, Aspen Pharmacare, Astellas, AstraZeneca, Pfizer, Novartis, GSK, Takeda, Bayer, Boehringer Ingelheim

Table Of Contents

Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

2.1. Introduction
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2010
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon - Ception - January 2009
2.6.2. Case study 2: Endo - Indevus - January 2009
2.6.3. The future of option to acquire deals

Chapter 3 - Overview of option and evaluation deal structure

3.1. Introduction
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: Idenix Pharmaceuticals - Janssen Pharmaceuticals - January 2013
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec - Isis Pharmaceuticals - June 2012
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis -Prometheus - January 2010
3.3.1.c. Option to finance
Case study 6: Amarantus BioSciences- Power3 Medical Products - January 2012
3.3.1.d. Option to co-promote
Case study 7: Teva - OncoGenex Pharmaceuticals - December 2009
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix - Nycomed - July 2007
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: ViroPharma- Meritage Pharma - December 2011
3.4.1.b. Case study 10: Nuvasive - Progentix Orthobiology - January 2009

Chapter 4 - Leading option and evaluation deals

4.1. Introduction
4.2. Top option and evaluation deals by value
4.3. Most active option and evaluation dealmakers
4.4. Big pharma option and evaluation deal activity
4.5. Big biotech option and evaluation deal activity

Chapter 5 - Big pharma option and evaluation deals

5.1. Introduction
5.2. How to use option and evaluation deals
5.3. Big pharma company option and evaluation deal profiles

Chapter 6 - Big biotech option and evaluation deals

6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech option and evaluation partnering company profiles

Chapter 7 - Option and evaluation contracts directory

7.1. Introduction
7.2. Option and evaluation deals by company A-Z
7.3. Option and evaluation deals by stage of development
7.4. Option and evaluation deals by therapeutic target
7.5. Option and evaluation deals by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Reports

TABLE OF FIGURES

Figure 1: Definition of option and evaluation deals
Figure 2: Types of option right
Figure 3: Trends in option and evaluation deal announcements, 2010-2015
Figure 4: Recent option-based deals
Figure 5: Example deals where co-promotion options have been actively exercised, since 2000
Figure 6: Recent ‘option to acquire' deals
Figure 7: Components of the option and evaluation deal structure
Figure 8: Types of option in an agreement
Figure 9: Attributes of option terms:
Figure 10: Top option and evaluation deals by value since 2010
Figure 11: Most active option and evaluation dealmakers 2010-2015
Figure 12: Big pharma - top 50 - option and evlaution deals 2010 to 2015
Figure 13: Big pharma option and evaluation deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - option and evaluation deals 2010 to 2015
Figure 15: Big biotech option and evaluation deal frequency - 2010 to 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.